jurnalul român de psihofarmacologie romanian journal of ...
jurnalul român de psihofarmacologie romanian journal of ... jurnalul român de psihofarmacologie romanian journal of ...
Jurnalul Român de Psihofarmacologie Romanian Journal of Psychopharmacology Vol. 6, Nr. 1, 2 10. Falkay P.,Wobrock T., Lieberman J., Glenthoj B., Gattaz W. F., Moller H. J, 2005 – WFSBP Task Force on Treatment Guidelines for Schizophrenia,World Federation of Societies of Biological Psychiatry (WFSBP), Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. The World Journal of Biological Psychiatry, 6(3), 132-191. 11. Gheorghe M.D., 1999 – Actualităţi în Psihiatria Biologică. Editura Intact, Bucureşti, 3(3.1, 3.2), 97-117,135-137. 12. Gheorghe M.D., Marinescu D.,Voicu V.A., 2006 – Antipsihoticele. Editura Academiei Romane, Bucureşti, 4, 79-90. 13. ICD-10 Classification of Mintal and Behavioreral Disorders: Clinical descriptions and Diagnostic Guidelines WHO – 1992. 14. Kane J, Honigfeld G, Singer J, Meltzer H., 1988 – Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch. Gen. Psychiat., 45, 789-/796. 15. Kasper S, Lerman MN, McQuade RD et al., 2003 – Efficacy and safety of aripiprazole vs. haloperidol for longterm maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol., 6, 325-337. 16. Kapur S, Remington G, 1996 – Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiat., 4, 153, 466-476. 17. Lieberman JA, Grochowski S, Mabugat L, 1994 – Clozapine effects on positive and negative symptoms a six-month trial in treatment-refractory schizophrenics. J Clin. Psychopharmacol., 14, 201-204. 18. Lieberman J. A., Tasman A. (2006) Handbook of Psychiatric Drugs, John Wiley &Sons Ltd, England, 1, 16-17 19. Marinescu D., Udrişoiu T., Chiriţă A., 2001 – Ghid terapeutic – Schizofrenia, Ed. Med. Universitaria, Craiova. 20. Meltzer HY., 1991 – The mechanism of action of novel antipsychotic drugs, Schizophr. Bull., 17, 263-287. 21. Meltzer HY., 1995 – The role of serotonin in schizophrenia and the place of serotonindopamine antagonist antipsychotics, J. Clin. Psychopharmacol. 15, 2S-3S. 22. Miller D.D., Perry P J, Cadoret RJ et al., 1994 – Clozapine’s effect on negative symptoms in treatment refractory schizophrenics. Compr. Psychiat., 35, 8-15. 23. Moller HJ, Boyer P, Fleurot O, Rein W., 1997 – Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol. Psychopharmacol., 132, 396-401. 54
Jurnalul Român de Psihofarmacologie Romanian Journal of Psychopharmacology Vol. 6, Nr. 1, 2 24. Moller HJ, 2003 – Management of the negative symptoms of schizophrenia. New treatment options. CNS drugs, 17(11), 793-823. 25. Peuskens J, Risperidone Study Group, 1995 – Risperidone in the treatment of patients with chronic schizophrenia: A multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Brit. J. Psychiat., 166, 712-726. 26. Peuskens J, Bech P, Moller HJ et al. (the Amisulpride Study Group), 1999 – Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Psychiat. Res., 88, 107-117. 27. Potkin SG, Saha AR, Kujawa MJ et al., 2003 – Aripiprazole, anantipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiat., 60, 681-690. 28. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG, 1997 – Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Arch. Gen. Psychiat., 54, 549-557. 29. Stahl SM., 2002 – Essential Psychopharmacology of Antipsychotics and Mood Stabilizers. Cambridge University Press; 1, 5-9. 30. Tandon R, Goldman R, DeQuardo J R et al., 1993 – Positive and negative symptoms covary during clozapine treatment in schizophrenia. J. Psychiat. Res, 27, 341-347. 31. Taylor D., Paton C., Kerwin R, 2003 – The Maudsley Prescribing Guidelines 2003, 7-th Edition, Martin Dunitz, London 2, 40-45. 32. Tollefson GD, Sanger TM., 1997 – Negative symptoms: A pathanalytic approach to a double-blind, placebo- and haloperidol controlled clinical trial with olanzapine. Am. J. Psychiat., 154, 466-474. 33. Waddington JL, Youssef HA, Kinsella A, 1995 – Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychol. Med., 25, 849-957. 55
- Page 7 and 8: Jurnalul Român de Psihofarmacologi
- Page 9 and 10: Jurnalul Român de Psihofarmacologi
- Page 11 and 12: Jurnalul Român de Psihofarmacologi
- Page 13 and 14: Jurnalul Român de Psihofarmacologi
- Page 15 and 16: Jurnalul Român de Psihofarmacologi
- Page 17 and 18: Jurnalul Român de Psihofarmacologi
- Page 19 and 20: Jurnalul Român de Psihofarmacologi
- Page 21 and 22: Jurnalul Român de Psihofarmacologi
- Page 23 and 24: Jurnalul Român de Psihofarmacologi
- Page 25 and 26: Jurnalul Român de Psihofarmacologi
- Page 27 and 28: Jurnalul Român de Psihofarmacologi
- Page 29 and 30: Jurnalul Român de Psihofarmacologi
- Page 31 and 32: Jurnalul Român de Psihofarmacologi
- Page 33 and 34: Jurnalul Român de Psihofarmacologi
- Page 35 and 36: Jurnalul Român de Psihofarmacologi
- Page 37 and 38: Jurnalul Român de Psihofarmacologi
- Page 39 and 40: Jurnalul Român de Psihofarmacologi
- Page 41 and 42: Jurnalul Român de Psihofarmacologi
- Page 43 and 44: Jurnalul Român de Psihofarmacologi
- Page 45 and 46: Jurnalul Român de Psihofarmacologi
- Page 47 and 48: Jurnalul Român de Psihofarmacologi
- Page 49 and 50: Jurnalul Român de Psihofarmacologi
- Page 51 and 52: Jurnalul Român de Psihofarmacologi
- Page 53 and 54: Jurnalul Român de Psihofarmacologi
- Page 55 and 56: Jurnalul Român de Psihofarmacologi
- Page 57: Jurnalul Român de Psihofarmacologi
- Page 61 and 62: Jurnalul Român de Psihofarmacologi
- Page 63 and 64: Jurnalul Român de Psihofarmacologi
- Page 65 and 66: Jurnalul Român de Psihofarmacologi
- Page 67 and 68: Jurnalul Român de Psihofarmacologi
- Page 69 and 70: Jurnalul Român de Psihofarmacologi
- Page 71 and 72: Jurnalul Român de Psihofarmacologi
- Page 73 and 74: Jurnalul Român de Psihofarmacologi
- Page 75 and 76: Jurnalul Român de Psihofarmacologi
- Page 77 and 78: Jurnalul Român de Psihofarmacologi
- Page 79 and 80: Jurnalul Român de Psihofarmacologi
- Page 81 and 82: Jurnalul Român de Psihofarmacologi
- Page 83 and 84: Jurnalul Român de Psihofarmacologi
- Page 85 and 86: Jurnalul Român de Psihofarmacologi
- Page 87 and 88: ASOCIAŢIA ROMÂNĂ DE PSIHOFARMACO
Jurnalul Român <strong>de</strong> Psih<strong>of</strong>armacologie<br />
Romanian Journal <strong>of</strong> Psychopharmacology<br />
Vol. 6, Nr. 1, 2<br />
24. Moller HJ, 2003 – Management <strong>of</strong> the negative symptoms <strong>of</strong> schizophrenia. New<br />
treatment options. CNS drugs, 17(11), 793-823.<br />
25. Peuskens J, Risperidone Study Group, 1995 – Risperidone in the treatment <strong>of</strong> patients<br />
with chronic schizophrenia: A multinational, multi-centre, double-blind, parallel-group<br />
study versus haloperidol. Brit. J. Psychiat., 166, 712-726.<br />
26. Peuskens J, Bech P, Moller HJ et al. (the Amisulpri<strong>de</strong> Study Group), 1999 –<br />
Amisulpri<strong>de</strong> versus risperidone in the treatment <strong>of</strong> acute exacerbations <strong>of</strong> schizophrenia.<br />
Psychiat. Res., 88, 107-117.<br />
27. Potkin SG, Saha AR, Kujawa MJ et al., 2003 – Aripiprazole, anantipsychotic with a<br />
novel mechanism <strong>of</strong> action, and risperidone vs placebo in patients with schizophrenia<br />
and schizoaffective disor<strong>de</strong>r. Arch. Gen. Psychiat., 60, 681-690.<br />
28. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG, 1997 – Quetiapine in patients<br />
with schizophrenia: A high- and low-dose double-blind comparison with placebo. Arch.<br />
Gen. Psychiat., 54, 549-557.<br />
29. Stahl SM., 2002 – Essential Psychopharmacology <strong>of</strong> Antipsychotics and Mood<br />
Stabilizers. Cambridge University Press; 1, 5-9.<br />
30. Tandon R, Goldman R, DeQuardo J R et al., 1993 – Positive and negative symptoms<br />
covary during clozapine treatment in schizophrenia. J. Psychiat. Res, 27, 341-347.<br />
31. Taylor D., Paton C., Kerwin R, 2003 – The Maudsley Prescribing Gui<strong>de</strong>lines 2003, 7-th<br />
Edition, Martin Dunitz, London 2, 40-45.<br />
32. Tollefson GD, Sanger TM., 1997 – Negative symptoms: A pathanalytic approach to a<br />
double-blind, placebo- and haloperidol controlled clinical trial with olanzapine. Am. J.<br />
Psychiat., 154, 466-474.<br />
33. Waddington JL, Youssef HA, Kinsella A, 1995 – Sequential cross-sectional and 10-year<br />
prospective study <strong>of</strong> severe negative symptoms in relation to duration <strong>of</strong> initially<br />
untreated psychosis in chronic schizophrenia. Psychol. Med., 25, 849-957.<br />
55
Change language